Startups
Luminopia
Luminopia, Inc. is a Cambridge, Massachusetts medical-device company developing prescription digital therapeutics for neuro-visual disorders. Its commercial amblyopia therapy uses proprietary video-processing algorithms and a virtual-reality headset to encourage use of the weaker eye and binocular visual integration while children watch licensed programming at home. FDA 510(k) clearance K243819, decided April 9, 2025, covers patients aged 4 to under 13 with amblyopia associated with anisometropia and/or mild strabismus, as an adjunct to full-time refractive correction under professional prescription. This clearance extends the earlier 2021 De Novo authorization; clinical and commercial claims are qualified as issuer statements. Neuroscience relevance arises from visual processing and binocular therapy; the published algorithms do not by themselves establish artificial-intelligence use. Delaware incorporation in 2015 is documented in the issuer’s SEC filing.
Founded 2015
Team
 Bruce KentNational Sales Director |
 Casey TanseyBoard Member |
 Drew MoweryVP of Commercial Strategy |
 Eric SingmanScientific Advisor |
 Hank WuCOO |
 Krystel HuxlinScientific Advisor |
 Marguerite McDonaldScientific Advisor |
 Mark JacobsteinBoard Member |
 Peter BexScientific Advisor |
 Peter J. McDonnellScientific Advisor |
 Robert F. HessScientific Advisor |
 Scott XiaoCo-Founder and CEO · Board Member |
 Shelley HancockSr Director, Medical Affairs |
 Stephanie RobertsHead of Market Access |
 Sunny AtwalVP of Engineering |
 William DaiBoard Member |
